Five Prime

FPRX NASDAQ
5.56
-0.19
-3.30%
After Hours: 5.56 0 0.00% 16:09 08/23 EDT
Open
5.74
Prev Close
5.75
High
5.82
Low
5.47
Volume
194.17K
Avg Vol (3M)
491.01K
52 Week High
16.00
52 Week Low
4.885
% Turnover
0.53%
Market Cap
204.50M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Five Prime FPRX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.
MORE >

Recently

Name
Price
%Change